ARPIT RAO

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
Houston, TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rao A, Antonarakis ES. The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. Expert Rev Anticancer Ther. 2022 May 26; 1-9. PMID: 35594523.
      Citations:    Fields:    
    2. Rao A, Moka N, Hamstra DA, Ryan CJ. Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? Cancers (Basel). 2022 Feb 04; 14(3). PMID: 35159068.
      Citations: 1     
    3. Rao A, Scher HI, De Porre P, Yu MK, Londhe A, Qi K, Morris MJ, Ryan C. Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open. 2020 11; 5(6):e000943. PMID: 33184097.
      Citations:    Translation:HumansCTClinical Trials
    4. Ganaie AA, Mansini AP, Hussain T, Rao A, Siddique HR, Shabaneh A, Ferrari MG, Murugan P, Klingelhöfer J, Wang J, Ambartsumian N, Warlick CA, Konety BR, Saleem M. Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. Mol Cancer Ther. 2020 12; 19(12):2598-2611. PMID: 32999046.
      Citations: 1     Fields:    Translation:HumansCells
    5. Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, Hallstrom C, Zorko NA, Rao A, Fujioka N, Ryan CJ, Geller MA, Miller JS, Felices M. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers (Basel). 2020 Sep 18; 12(9). PMID: 32961861.
      Citations: 11     
    6. Watson AP, Shabaneh A, Wang J, Dehm SM, Rao A, Ryan CJ. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53, PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. Am J Clin Exp Urol. 2020; 8(4):106-115. PMID: 32929406.
      Citations: 1     
    7. Rao A, Antonarakis ES. Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility? Ann Transl Med. 2019 Dec; 7(Suppl 8):S354. PMID: 32016072.
      Citations:    
    8. Loudas NB, Killeen AA, Palamalai V, Weight CJ, Rao A, Cho LC. Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature. Am J Case Rep. 2019 Aug 24; 20:1248-1252. PMID: 31444319.
      Citations:    Fields:    Translation:Humans
    9. Rao A, Vapiwala N, Schaeffer EM, Ryan CJ. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:309-320. PMID: 31099652.
      Citations: 7     Fields:    Translation:Humans
    10. Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol. 2019 Jan-Dec; 11:1756287218823485. PMID: 30728859.
      Citations: 5     
    11. Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. Ann Transl Med. 2018 May; 6(9):165. PMID: 29911113.
      Citations: 13     
    12. Wong M, Rao A, Nemunaitis J, Czuchlewski D, Sagheer S, Arana-Yi C. Hemophagocytosis lymphocytosis presenting as pulmonary-renal syndrome: a case report and literature review. Clin Case Rep. 2017 09; 5(9):1486-1489. PMID: 28878910.
      Citations: 1     
    13. Rao A, Lauer R. Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist. 2015 Apr; 20(4):370-1. PMID: 25777345.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    14. Rao A, Sasapu A, Jiwani S, Laryea J, Makhoul I. Diffuse large B-cell lymphoma of the colon--a rare presentation. J Ark Med Soc. 2015 Mar; 111(10):208-10. PMID: 25831631.
      Citations:    Fields:    Translation:Humans
    15. Rao A, Griffiths R, Arnaoutakis K. Paralyzed by a rare cause: an unusual case of metastatic diffuse large B cell lymphoma of the intramedullary spinal cord. Ann Hematol. 2014 Feb; 93(2):337-8. PMID: 23712293.
      Citations: 1     Fields:    Translation:Humans
    16. Agrawal CS, Tiwari P, Mishra S, Rao A, Hadke NS, Adhikari S, Srivastava A. Interrupted abdominal closure prevents burst: randomized controlled trial comparing interrupted-x and conventional continuous closures in surgical and gynecological patients. Indian J Surg. 2014 Aug; 76(4):270-6. PMID: 25278649.
      Citations: 4     
    RAO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (53)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _